NCT01164540View on ClinicalTrials.gov

Study on the Effect of Rosuvastatin Treatment on the Prevention of Thrombosis in Patients With Previous Thrombosis

PHASE3WithdrawnINTERVENTIONAL
Enrollment

3,000

Participants

Timeline

Start Date

February 28, 2011

Primary Completion Date

March 31, 2013

Study Completion Date

March 31, 2013

Conditions
Venous ThrombosisPulmonary Embolism
Interventions
DRUG

Rosuvastatin (AZD4522)

Oral dose (od) 20 mg

DRUG

Placebo

Oral dose (od)

Sponsors

Lead Sponsor

AstraZeneca
All Listed Sponsors
lead

AstraZeneca

INDUSTRY